Case Study

Global Omnichannel Governance

How a global pharma brand identified cross-market inconsistencies, established AI governance workflows, and reduced narrative drift by 42%.

Last updated: January 2026

On this page

Snapshot

Brand Type
Large pharma, established brand
Therapeutic Area
Metabolic / Endocrinology
Stage
Post-launch (3+ years on market)
Geography
8 markets (US, EU5, Japan, Australia)
Time Window
6-month governance program
LLMs Monitored
ChatGPT, Claude, Gemini, Perplexity

The Challenge

A global pharmaceutical company marketed an established metabolic therapy across multiple geographies. Over time, messaging had evolved differently in each market based on local medical practices, competitive dynamics, and regional marketing teams.

This created several challenges:

  • Fragmented positioning: The brand was described differently across markets - as "first-line" in some, "second-line after failure" in others, and with varying emphasis on specific benefits.
  • AI amplified inconsistencies: AI systems drew from content across all markets, sometimes synthesizing contradictory positioning into single answers[2].
  • Compliance risk across jurisdictions: What was approved messaging in one country might be non-compliant in another. AI didn't distinguish between regulatory environments[3, 4].
  • Governance gaps: No single team owned AI monitoring. Issues fell between corporate, regional, and local responsibilities with no clear escalation path.
  • MLR bottleneck: When issues were identified, corrective content moved slowly through fragmented MLR processes, allowing problems to persist.

What AI Pulse Found

AI Pulse established monitoring across all 8 markets with localized question sets reflecting regional terminology and treatment patterns. The analysis revealed significant issues.

Cross-Market Inconsistencies

The baseline uncovered 23 messaging inconsistencies where AI presented conflicting information depending on sources:

Examples of inconsistencies found:

  • Positioning conflict: US sources emphasized "cardiovascular benefit" prominently; EU sources focused on "glycemic control." AI sometimes mentioned one, sometimes the other, sometimes contradictory combinations.
  • Dosing variations: Regional labeling differences meant AI occasionally surfaced dosing information from one market in response to questions from another market context.
  • Competitive framing: In markets where competitor X was strong, local content positioned against X. AI sometimes applied that competitive framing in markets where X wasn't relevant.

Drift Patterns

Week-over-week monitoring revealed narrative drift patterns:

  • A competitor's new data publication shifted AI positioning toward that competitor within 2 weeks of publication.
  • An outdated safety concern (addressed in updated labeling) resurfaced in AI answers, likely from older source content.
  • Seasonal patterns: AI mentioned certain benefits more during periods when related content (conference presentations, press releases) was published.

Drift was gradual but cumulative. Without continuous monitoring, each small shift went unnoticed until the overall positioning diverged significantly from intended messaging.

Compliance Risks

PI-backed verification flagged 18 compliance concerns across markets:

6

Not-in-PI claims

12

Ambiguous claims

4

Fair balance concerns

Several Not-in-PI claims stemmed from market-specific content appearing in responses for other markets where those claims weren't approved.

Actions Taken

The global brand team established a cross-functional AI governance program:

  1. Global governance queue: Created a single queue with routing rules to direct findings to appropriate regional owners. Corporate retained visibility; locals owned resolution. Every finding had a named owner, due date, and audit trail.
  2. Messaging harmonization: Corporate Medical Affairs convened a cross-market working group to align core messaging pillars. Not all messaging became identical (regulatory environments differ), but key positioning statements were harmonized.
  3. Source consolidation: Identified the highest-impact sources AI cited across markets. Prioritized updating those sources with consistent, globally-aligned content. Deprecated outdated regional content where possible.
  4. MLR fast-track: Established a streamlined MLR review process for AI-related corrective content. Reduced approval cycle for "AI response corrections" from 4 weeks average to 1.5 weeks.
  5. Weekly monitoring cadence: Implemented weekly AI Pulse retests to catch drift early. Dashboard showed trends by market and provider, enabling proactive response.

Retest Outcome

After 6 months of governance implementation, measurable improvements appeared:

Narrative Drift Flags

42% reduction

From 23 to 13 inconsistencies

MLR Review Cycle

28% faster

4 weeks → 2.9 weeks average

Not-in-PI Claims

6 → 2

4 resolved, 2 in progress

Cross-Market Alignment Score

64 → 81

Measured consistency across markets

The remaining inconsistencies were tracked as known issues with documented justifications (regulatory differences requiring market-specific positioning).

What Changed Operationally

Beyond metrics, the governance program transformed operations:

  • Clear ownership model: AI monitoring moved from "nobody's job" to a defined responsibility matrix. Corporate owned global consistency; regions owned local resolution; Medical Affairs owned compliance triage.
  • Audit trail for compliance: Every finding, action, and outcome was documented. When regulators or internal audit asked about AI accuracy, the team had evidence of systematic monitoring and response.
  • Omnichannel integration: AI visibility joined the omnichannel dashboard alongside website, rep interactions, and other touchpoints[6]. Teams saw AI as a channel to govern, not an external force to ignore.
  • Proactive vs reactive: With weekly monitoring, the team caught drift early - before it compounded into major positioning problems. Response time to competitive publications improved from weeks to days.
  • Executive visibility: Quarterly AI Pulse reports went to brand leadership, demonstrating the team's proactive approach to an emerging risk area.

Disclaimer

Anonymized Composite: This case study is a composite example based on common scenarios encountered by global pharmaceutical brand teams. Company names, specific metrics, and details have been generalized and anonymized. It is intended for illustration purposes to demonstrate typical AI governance challenges and outcomes, not to represent a specific client engagement.

Citations

  1. [1] OpenAI - Introducing ChatGPT Health (Jan 7, 2026) https://openai.com/index/introducing-chatgpt-health/
  2. [2] Healthcare Dive - More than 40 million people ask ChatGPT healthcare questions every day (Jan 6, 2026) https://www.healthcaredive.com/news/40-million-use-chatgpt-health-questions-openai/808861/
  3. [3] Covington - 2023 End-of-Year Summary of FDA Advertising and Promotion Enforcement Activity (Jul 22, 2024) https://www.cov.com/en/news-and-insights/insights/2024/07/2023-end-of-year-summary-of-fda-advertising-and-promotion-enforcement-activity
  4. [4] FDA OPDP The Brief Summary (Jan 2025 PDF) https://www.fda.gov/media/185040/download
  5. [5] IQVIA case study - 27% increase therapy starts (Apr 20, 2023) https://www.iqvia.com/library/case-studies/increasing-therapy-starts-though-ai-powered-precise-patient-identification-field-alerts
  6. [6] ZS - Unified engagement / omnichannel context (Apr 15, 2025) https://www.zs.com/insights/unified-engagement-goal-pharma-marketing

Related Reading